Прогностические факторы исхода пациентов с хронической обструктивной болезнью легких (по результатам проспективного динамического наблюдения)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2017. https://www.goldcopd.com
2. Lamprecht B, McBurnie MA, Vollmer WM et al. BOLD Collaborative Research Group: COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 2011; 139: 752–63.
3. Chuchalin AG, Khaltaev N, Antonov NS et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J COPD 2014; 12: 963–74.
4. World Health Organization. Evidence-informed policy-making. 2016. http://www.who.int/evidence
5. Mannino DM, Homa DM, Akinbami LJ et al. Chronic Obstructive Pulmonary Disease Surveillance – United States, 1971-2000. MMWR Surveillance Summaries 2002; 51 (SS06): 1–16.
6. Garcia IS, Clara PC. Causes of death and prediction of mortality in COPD. Arch Bronconeumol 2010; 46: 343–6.
7. Calverley PMA, Anderson JA, Celli B et al. Cardiovascular events in patients with COPD: TORCH Study results. Thorax 2010; 65: 719–25.
8. Garsia-Aymerich J, Lange P, Benet M, Schnohr P et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006; 61 (9): 772–8.
9. O'Donnell DE. Assessment of bronchodilatator efficacy in symptomatic COPD: Is spirometry useful? Chest 2000; 117: 42–7.
10. Vestbo J, Prescott E, Lange P et al. Vital prognosis after hospitalization for COPD: a study of a random population sample. Respite Med 1998; 92. 772–6.
11. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995; 122: 823–32.
12. Pinto-Plata VM, Celli-Cruz RA, Vassaux C et al. Differences in cardiopulmonary exercise test results by American Thoracic Society. European Respiratory Society – Global initiative for chronic obstructive lung disease stage categories and gender. Chest 2007; 132: 1204–11.
13. Авдеев С.Н. Хроническая обструктивная болезнь легких: обострения. Пульмонология. 2013; 3: 5–18. / Avdeev S.N. Khronicheskaia obstruktivnaia bolezn' legkikh: obostreniia. Pul'monologiia. 2013; 3: 5–18. [in Russian]
14. Fletcher С. Discussion on the Diagnosis of Pulmonary Emphysema. JR soc Med 1952; 45: 576–86. http://journals.sagepub.com/doi/pdf
15. Kesser R, Partridge MR, Miravitles M et al. symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011; 37: 264–72.
16. Hurst JR, Vestbo J, Anzueto A et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128–38.
17. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434–40.
18. Divo M, Cote C, de Torres JP et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155–61.
19. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? Circulation 2003; 107: 1514–9.
20. Fuso L, Incalzi RA, Pistelli R et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995; 98: 272–7.
21. Hansen EF, Phanareth K, Laursen LC et al. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1267–71.
22. Barbara C, Moita J, Cardoso J et al. The importance of dyspnea in the diagnosis of chronic obstructive pulmonary disease – a descriptive analysis of a stable cohort in Portugal (SAFE Trial). Rev Port Pneumol 2011; 17: 131–8.
23. Engstrom G, Lind P, Hedblad B et al. Lung function and cardiovascular risk: relationship with inflammation – sensitive plasma proteins. Circulation 2002; 106: 2555–60.

________________________________________________

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2017. https://www.goldcopd.com
2. Lamprecht B, McBurnie MA, Vollmer WM et al. BOLD Collaborative Research Group: COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 2011; 139: 752–63.
3. Chuchalin AG, Khaltaev N, Antonov NS et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J COPD 2014; 12: 963–74.
4. World Health Organization. Evidence-informed policy-making. 2016. http://www.who.int/evidence
5. Mannino DM, Homa DM, Akinbami LJ et al. Chronic Obstructive Pulmonary Disease Surveillance – United States, 1971-2000. MMWR Surveillance Summaries 2002; 51 (SS06): 1–16.
6. Garcia IS, Clara PC. Causes of death and prediction of mortality in COPD. Arch Bronconeumol 2010; 46: 343–6.
7. Calverley PMA, Anderson JA, Celli B et al. Cardiovascular events in patients with COPD: TORCH Study results. Thorax 2010; 65: 719–25.
8. Garsia-Aymerich J, Lange P, Benet M, Schnohr P et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006; 61 (9): 772–8.
9. O'Donnell DE. Assessment of bronchodilatator efficacy in symptomatic COPD: Is spirometry useful? Chest 2000; 117: 42–7.
10. Vestbo J, Prescott E, Lange P et al. Vital prognosis after hospitalization for COPD: a study of a random population sample. Respite Med 1998; 92. 772–6.
11. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995; 122: 823–32.
12. Pinto-Plata VM, Celli-Cruz RA, Vassaux C et al. Differences in cardiopulmonary exercise test results by American Thoracic Society. European Respiratory Society – Global initiative for chronic obstructive lung disease stage categories and gender. Chest 2007; 132: 1204–11.
13. Avdeev S.N. Khronicheskaia obstruktivnaia bolezn' legkikh: obostreniia. Pul'monologiia. 2013; 3: 5–18. [in Russian]
14. Fletcher С. Discussion on the Diagnosis of Pulmonary Emphysema. JR soc Med 1952; 45: 576–86. http://journals.sagepub.com/doi/pdf
15. Kesser R, Partridge MR, Miravitles M et al. symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011; 37: 264–72.
16. Hurst JR, Vestbo J, Anzueto A et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128–38.
17. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434–40.
18. Divo M, Cote C, de Torres JP et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155–61.
19. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? Circulation 2003; 107: 1514–9.
20. Fuso L, Incalzi RA, Pistelli R et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995; 98: 272–7.
21. Hansen EF, Phanareth K, Laursen LC et al. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1267–71.
22. Barbara C, Moita J, Cardoso J et al. The importance of dyspnea in the diagnosis of chronic obstructive pulmonary disease – a descriptive analysis of a stable cohort in Portugal (SAFE Trial). Rev Port Pneumol 2011; 17: 131–8.
23. Engstrom G, Lind P, Hedblad B et al. Lung function and cardiovascular risk: relationship with inflammation – sensitive plasma proteins. Circulation 2002; 106: 2555–60.

Г.Л.Игнатова, Е.В.Блинова, В.Н.Антонов

ФГБОУ ВО «Южно-Уральский государственный медицинский университет» Минздрава России. 454092, Россия, Челябинск, ул. Воровского, д. 64

*iglign@mail.ru

________________________________________________

G.L.Ignatova, E.V.Blinova, V.N.Antonov

Medical University of South Ural State of the Ministry of Health of the Russian Federation. 454092, Russian Federation, Chelyabinsk, ul. Vorovskogo, d. 64

*iglign@mail.ru